UNSPSC 51183610: Insulin glargine

This classification denotes a therapeutic insulin with the molecular formula C267H404N72O78S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2ZM8CX04RZ, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG.

UNSPSC 51183610 Insulin glargine is a Commodity code covering a specific pharmaceutical product supplied through state and local procurement channels. State and local governments procure insulin glargine primarily through cooperative purchasing vehicles and multistate agreements that consolidate demand across participating agencies, schools, transit authorities, and other public bodies. The work involves manufacturers and authorized pharmaceutical wholesalers responding to requests for proposal that specify product availability, pricing structures, wholesaler relationships, compliance certifications, and contractual terms spanning two years or longer with optional extensions. Issuing bodies include state procurement offices administering multistate cooperative purchasing alliances and the member agencies—state departments, county health systems, school districts, and other public entities—that access the resulting contracts for pharmaceutical supply to their facilities and programs.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with response due March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026 and resulting agreements effective July 1, 2026. Evaluation weighted price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing, administrative compliance, EDI capability, and a required 3 percent administrative fee. Vendors must maintain $5 million commercial general liability coverage, $2 million network security and privacy liability, and $2 million professional liability, comply with cGMP and DSCSA requirements, and demonstrate pricing flexibility through flat-price, net-price, or WAC-minus structures. The contract term is two years for new responders with optional extensions at MMCAP's discretion, and the RFP does not identify specific set-aside restrictions.